Cipla, Pharma Giant on Wednesday has announced that it has launched its generic version of antiviral drug remdesivir at Rs 4,000 per vial, which is among the lowest globally, and is looking to supply over 80,000 vials within the first month. Cipremi is priced at Rs 4,000 per 100 mg vial, according to the statement by Cipla.
Nikhil Chopra said in an e-mailed statement that, “We are proud to commercially launch Cipremi today (on Wednesday); amongst the lowest priced globally, and aim to supply over 80,000 vials within the first month itself,” Cipla Executive Vice-President and CEO (India Business).To further ensure equitable distribution, the drug will be available through government and hospital channels only, he added. “Cipla will also be donating some amount of the drug as part of its efforts to support the community in this time of need.
The Drug Controller General of India has approved Cipremi for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.
Remdesivir has been approved by United States Food and Drug Administration (USFDA) for Emergency Use Authorisation (EUA) treatment for adult and pediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection.
Earlier in May, pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.
